Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics, MilliporeSigma Collaborate on CRISPR Screening Workflow

NEW YORK – MilliporeSigma and 10x Genomics announced on Wednesday a collaboration on single-cell CRISPR screening workflows.

The workflows will combine MilliporeSigma's CRISPR genome editing reagents with 10x's Feature Barcode assay to enable single-cell screens for changes in gene expression that result from those edits.

"There has been and continues to be extensive interaction between our R&D teams to test and validate our CRISPR vectors with compatibility on the 10x Genomics platform," a MilliporeSigma spokesperson wrote in an email. The firms also have a commercial arrangement under which they plan to put on joint webinars. Financial and other details of the collaboration were not disclosed.

The collaboration will take place under 10x's Compatible Partnership Program. MilliporeSigma is the life sciences business of Germany's Merck KGaA and operates under that name in the US, Canada, and Puerto Rico.

Andrew Bulpin, head of process solutions at MilliporeSigma, said in a statement that the combined technologies will enable "the identification of novel molecular therapeutic targets and accelerate drug discovery in immuno-oncology, autoimmunity, neurodegeneration and other human diseases."

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.